ArticleGynecologic oncology reports2023

Rucaparib for PARP inhibitor-pretreated ovarian cancer: A GEICO retrospective subgroup analysis from the Spanish Rucaparib Access Program.

Alfonso Yubero et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.